Egfr inhibition in a pretreated sacral chordoma: a rolefor erlotinib? Case report and a brief review of literature by Trapani, Dario et al.
Translational Medicine @ UniSa - ISSN 2239-9747 2017, 16(5): 30-33
 
30 
Università degli Studi di Salerno 
  
 
Abstract - We describe the case of a 69-year old 
male with an EGFR- positive Imatinib refractory 
sacral chordoma with synchronous lung metastases, 
treated with erlotinib, a first- generation EGFR 
inhibitor. After disease progression following first-
line Imatinib and a combination therapy with 
everolimus plus metformin, we made a challenge 
with an EGFR tyrosine kinase inhibitor (EGFR TKI), 
erlotinib. Despite a brief clinical benefit, the patient 
presented a rapid clinical deterioration leading to 
death, after 8 weeks of treatment. 
 






A 69-year old man was referred to our institution for a 
refractory sacral chordoma.  
First diagnosis was performed in April 2012 through an 
incisional biopsy of the primitive tumor; at presentation, 
synchronous lung metastases were radiologically detected. 
The primitive mass was surgically resected en-bloc with 
distal sacrum (distal sacrectomy): pathology report 
confirmed the presence of a 12, 5 cm chordoma, 
infiltrating the surrounding soft tissues and the overlying 
skin with ulceration. IHC (immunohistochemistry) 
revealed a Brachyury, PDGFR-β and EGFR 2+ positive 
tumor (R pharmDx™ Dako kit) with evidence of pS6 











He received a first-line systemic therapy with a tyrosine 
kinase inhibitor (TKI), Imatinib 400mg, in another 
institution; everolimus was added to imatinib for a slight 
progression of disease (PD) after 4 months, reaching a 
disease stability (SD) for 16 months; the TKI was 
eventually substituted with metformin with SD.  
The patient was then referred to our institution: he 
presented a rapid clinical deterioration of the clinical 
status with dyspnea on exertion; a low flow oxygen-
therapy on demand was so provided. We performed a 
18FDG-PET evaluation on July 2015 that revealed lung, 
bone and pelvic diffuse pathological accumulations. 
Afterwards, in the absence of therapeutic alternative 
options for a good performing patient, a challenge with an 
EGFR inhibitor, Erlotinib 150mg daily, was proposed. 
A better tolerance to exercise with a reduction of dyspnea 
on exertion and no more continuous, daily demand of 
oxygen support was reported. However, despite a transient 
clinical benefit, the patient presented a new rapid clinical 
deterioration after 8 weeks of treatment, leading to death 
in September 2015. 
 
DISCUSSION 
Chordoma is a rare mesenchymal tumor arising from the 
remnants of notochord, an embryonic midline structure 
common to all Chordata- Phylum members. In higher 
vertebrates including humans, the notochord gets ossified 
and contributes to the formation of vertebrae, persisting as 
nucleus pulposus of intervertebral discs (1); however, 
microscopic foci can remain in the cranial and caudal 
portion of the spine. Chordoma is a rare bone cancer, 
accounting 1- 4% of all bone malignancies; it arises 
mainly from the axial skeleton, affecting most commonly 
cranial and caudal bone midline sites like sacrum and 
skull base (2). 
The clinical behavior of this tumor is insidious for the 
unpredictable possibility of spread on bone and neural 
structures; moreover, the indolent and clinically silent 
course delays the diagnosis until advanced disease. 
Mostly, spine chordomas involve S4-S5 or coccygeal 
region protruding anteriorly into the pelvis with late onset 
neurological symptoms, due to neural roots compression 
(3). Chordoma rarely presents as metastatic at first 
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diagnosis: OS seems to be poorly affected by metastatic 
progression and local control appears to be correlated 
more to the prognosis (4). 
The backbone of therapy for the localized disease is 
surgery with wide margins without violation of tumor 
capsule, with a significant impact on DFS and OS (5). 
Concerning medical treatment, chordoma seems to be 
insensitive to cytotoxic chemotherapy; in a series of 33 
cases published by Azzarelli (6), no chemotherapeutic 
regimen induced a significant tumor respons though a 
potential response to continuous infusion ifosfamide was 
demonstrated in high-grade de-differentiated tumors (7) as 
well as with combination regimen containing  
anthracyclines, platinum-compounds and alkylating drugs 
(8).  
This intrinsic chemo-resistance paves the way to different 
anti-tumor approaches, designed from biologic features 
and molecular characterization of chordoma. Kilgore S. 
showed a high expression of cyclin D1, a key regulator of 
cell cycle-progression in a series of 26 chordoma samples 
(9); overexpression of CDK4, p53 and MDM2 was 
detected in 20-56% of sacral and skull- base chordoma, 
with a poor prognostic significance (10). Membrane 
growth factor receptors (TKRs) were demonstrated to be 
highly expressed in chordomas: scatter factor/ hepatocyte 
growth factor receptor (c-Met), epidermal growth factor 
receptor (EGFR/HER1) and different phosphorylated 
platelet-derived growth factor receptors (PDGFRs) seem 
to play a key role in tumor proliferation (11); this suggests 
a potential role of tyrosine-kinase receptor inhibitor as 
therapeutics. Hence, a high- level copy number gain of 
7p12 band (EGFR locus) and EGFR expression (67-81%) 
have been demonstrated; TKRs (PDGFR-a, c-Met, EGFR) 
are variously expressed in 97% of the recurrence samples 
analyzed (12).  
Furthermore, this molecular stigmata are potentially 
druggable. TKIs targeting angiogenesis have shown to be 
active against chordoma; this may probably reflect a 
cross- inhibition of different overlapping molecular 
patterns (13). On this subject, Casali et. al detected an 
anti-tumor effect in term of tumor liquefaction, metabolic 
and clinical response of imatinib mesylate 800mg daily; 
he supposed an activity mediated by PDGFRβ-inhibition 
(14). Similarly, a response to sunitinib 37,5 mg daily was 
demonstrated in a multicenter phase-II trial: 44% of 
chordoma patients achieved a SD concurrent to a 
qualitative decrease in tumor density; this pattern of 
response is considered to be characteristic of tumor 
response to VEGF-directed therapy (15). Additionally, 
EGFR-inhibitors have shown a clinical activity, 
particularly in the second-line setting after imatinib failure 
(16). Results from a phase II trial reported a modest 
antitumor activity of lapatinib administered at 1500mg 
continuously until progression or unacceptable toxicity in 
advanced EGFR-positive chordomas; the clinical benefit 
rate was 22,2% by RECIST for the intention-to-treat 
population (17).  
Siu  evaluated the activity of erlotinib on a patient-derived 
chordoma xenograft; he showed a strong druggable 
activation of EGFR: exposure of tumor cells to erlotinib 
resulted in a dimensional anti-tumor response concurrent 
to a reduction of phosphorylation of Tyr845 residue, thus 
supporting a favorable clinical usage (18). 
Based on this molecular notion, a compassionate use of 
Erlotinib for relapsed- refractory chordoma can be 
proposed. Few recent case reports showed a clinical 
activity of erlotinib (Tab1) but its benefit has not been 
evaluated in a prospective trial. Indeed, a sustained 
response to erlotinib of a clivus-arising chordoma after 
imatinib failure has been described by Houessinon A. 
(19): a 28 months continuous partial-response was 




Our case report shows no clear clinical response to 
erlotinib in an imatinib-refractory sacral chordoma. Few 
clinical data are available to support the choice of 
Erlotinib in this setting, with discordant experiences 
reported. Therefore, a prospective trial comparing 
erlotinib Vs. standard therapy in different setting is 
warranted, considering the high rate of EGFR- positive 
chordomas and preclinical encouraging data. Furthermore, 
EGFR mutational status prognostic significance and 
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Table 1. Cases of chordoma treated with erlotinib 150mg 
single- agent.  
 
 
Sur: surgery; RT: radiotherapy; PR: partial response according to 
RECIST criteria; WT: wild type; OG: response ongoing at time of case 
report writing; post-op: post-operative; IHC: immunohistochemistry; 
FISH: fluorescence in-situ hybridization; EGFR: epidermal growth 
factor receptor; PDGF: platelet- derived growth factor.  
 












Male  Sacrum  Sur: distal sacral and coccygeal 
resection  
 
RT: 66Gy for local relapse 
 


















PR 11 OG Singhal N, 2009 
[20] 
Male Sacrum  Sur: distal sacral and coccygeal 
resection 
 
Post-op 60Gy RT  
 
Bone metastasis resection and 
RT  
 
Imatinib 400mg  
 
Imatinib 600mg  
EGFR WT  
 
(chromosome 7 
trisomy in 38% of 
the tumor cells) 
IHC: 90% 
EGFR positive 














Clivus  Sur: transphenoidal tumor 
resection 
 





Not reported Not reported  PR  28 OG Houessinon A, 
2015 [19] 
ocalizati
on  
